Dr. Michael Keller, MD
Claim this profileChildren's National Hospital
Studies Primary Immunodeficiency
Studies Coronavirus
4 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Michael Keller, MD is currently running
Genetic Sequencing
for Immune Disorders
Background: Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems. Objective: To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol. Eligibility: Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives Design: Researchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people. Participants will receive results that: * Are important to their health * Have been confirmed in a clinical lab * Suggest that they could be at risk for serious disease that may affect your current or future medical management. Some genetic information we return to participants may be of uncertain importance. If genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report: * Normal variants * Information about progressive, fatal conditions that have no effective treatment * Carrier status (conditions you don t have but could pass on) The samples and data will be saved for future research. Personal data will be kept as private as possible. If future studies need new information, participants may be contacted.
Recruiting1 award N/A10 criteria
T Cell Therapy
for COVID-19
This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and \<80 years) HSCT recipients (Arm A) and two arms for pediatric (≥12 years of age and \<18 years; ≥2 years and \<12 years) HSCT recipients (Arm B and Arm C, respectively), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity.
Recruiting1 award Phase 123 criteria
More about Michael Keller, MD
Clinical Trial Related8 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michael Keller, MD has experience with
- Coronavirus-specific T Cell (CST)
- Centralized Sequencing Protocol
- Norovirus-specific T-cell (NST) Therapy
- Elapegademase-lvlr
Breakdown of trials Michael Keller, MD has run
Primary Immunodeficiency
Coronavirus
COVID-19
Nail Conditions
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Keller, MD specialize in?
Michael Keller, MD focuses on Primary Immunodeficiency and Coronavirus. In particular, much of their work with Primary Immunodeficiency has involved treating patients, or patients who are undergoing treatment.
Is Michael Keller, MD currently recruiting for clinical trials?
Yes, Michael Keller, MD is currently recruiting for 3 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Michael Keller, MD has studied deeply?
Yes, Michael Keller, MD has studied treatments such as Coronavirus-specific T cell (CST), Centralized Sequencing Protocol, Norovirus-specific T-cell (NST) therapy.
What is the best way to schedule an appointment with Michael Keller, MD?
Apply for one of the trials that Michael Keller, MD is conducting.
What is the office address of Michael Keller, MD?
The office of Michael Keller, MD is located at: Children's National Hospital, Washington, District of Columbia 20010 United States. This is the address for their practice at the Children's National Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.